Transgene provides business update and Q1 2023 financial position Dr. Alessandro Riva, MD, appointed as the Company’s Chairman and CEO to accelerate the development of Transgene’s innovative immunotherapy portfolio New clinical data to be communicated in Q2 2023 on TG4001, TG4050...